Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III

Executive Summary

Positive data from a second Phase III trial sets up Motif Bio for an NDA filing by the end of the year for novel antibiotic iclaprim – but success for the product has been a long time coming.

Advertisement

Related Content

Money Too Tight To Mention At Motif After Iclaprim 'No' From FDA
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US
Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion
Spring Awakening: NDA Submissions To Watch For
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
Roche Goes Back To Nature With Warp Drive Antibiotic Pact
Motif A Step Closer To Succeeding With Iclaprim After Phase III Success
Pulling iclaprim out of the ashes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099607

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel